Overview

Dihexa is an oligopeptide-derived small molecule developed from angiotensin IV. It is described in the literature as binding hepatocyte growth factor (HGF) and potentiating HGF/c-Met receptor signalling.

In the laboratory it is used in HGF/c-Met activation assays and in neuronal cell-culture models of dendritic-spine and synapse formation. No claims are made regarding effects in humans or animals.

Typical in-vitro applications

• HGF/c-Met receptor phosphorylation assays
• Neuronal cell-culture models of synaptogenesis
• HGF dimerisation studies

Compound data

• Compound: Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)
• Compound class: Angiotensin IV–derived peptidomimetic
• Target pathway: HGF / c-Met
• Net content: 10 mg per vial (stated for analytical and preparative calculations)
• Purity specification: ≥99% (HPLC); measured value on the lot certificate of analysis
• Form: Solid powder
• Intended use: In-vitro laboratory research only

Storage & handling

• Store the sealed vial at −20 °C, dry and protected from light.
• Allow the vial to reach room temperature before opening to avoid condensation.
• Handle with standard laboratory protective equipment (gloves, lab coat, eye protection).
• Shipped at ambient temperature in insulated, tamper-evident packaging.

Analytical documentation

HPLC purity and LC-MS identity are tested for every lot. Certificates of analysis and third-party test reports are published in our COA library on the About Us page.

For laboratory research use only. Not for human or veterinary use. See our Research Use Disclaimer.